This PD-1 target evaluation report is generated based on structured data from PatSnap Target &…
Browsing: oncology
This EGFR target evaluation report is generated based on structured data from PatSnap Target &…
Target Attractiveness Report · Oncology This KRAS target evaluation report is generated based on structured…
CD19 remained the dominant target for B-cell malignancy therapies in ASCO 2026 hematology presentations. Tafasitamab’s…
Nectin4 was an emerging ADC target in ASCO 2026 abstracts, with multiple new candidates entering…
HER2 was a central focus in ASCO 2026 targeted therapy and ADC presentations, with multiple…
TROP2 remained the leading ADC target in ASCO 2026 presentations, with multiple ADCs targeting this…
EGFR was the most heavily featured oncogenic driver target in ASCO 2026 targeted therapy abstracts,…
CTLA4 was a key immune checkpoint target in ASCO 2026 oral presentations, with multiple bispecific…
Notably, This report was generated using Eureka LS, an AI-powered competitive landscape intelligence platform. All…